Rockwell Medical, Inc. announced the appointment of Russell H. Ellison, MD, MSc, to its Board of Directors, effective January 9, 2020. Dr. Ellison has held leadership positions in both emerging biotechnology and large pharmaceutical companies for more than four decades. His broad experience includes board of director, chief executive and medical executive roles, with expertise in medical strategy, clinical development, global medical affairs, regulatory affairs and public health policy in major markets and developing countries. Dr. Ellison has a deep understanding of the renal space based on experiences with companies developing therapeutic products that address kidney disease and renal anemia, including Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors. Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc., which focused on, among other indications, kidney fibrosis, and successfully completed the company’s strategic sale in December 2018; President and CEO of Bond Biosciences, Inc., a biotech start up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC; Chairman and CEO of Assembly Biosciences, Inc. (formerly, Ventrus Biosciences, Inc.); Executive Vice President of Paramount Biosciences LLC, Vice President of Clinical Development at FibroGen, Inc. where he played a key role in the completion of a phase 2 trial with a HIF-PH inhibitor in anemia for Chronic Kidney Disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, Inc.; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc.